Ascendis Pharma A/S Sponsored ADR Forecast, price target & analysts
Ascendis Pharma A/S Sponsored ADR Target price 2025 - Analyst rating & recommendation
Ascendis Pharma A/S Sponsored ADR Classifications & Recommendation:
Ascendis Pharma A/S Sponsored ADR Price Target
| Target Price | $217.88 |
| Price | $165.05 |
| Potential |
32.01%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Ascendis Pharma A/S Sponsored ADR 2026 .
The average Ascendis Pharma A/S Sponsored ADR target price is $217.88.
This is
32.01%
register free of charge
$298.45
80.82%
register free of charge
$169.09
2.45%
register free of charge
|
|
| A rating was issued by 17 analysts: 16 Analysts recommend Ascendis Pharma A/S Sponsored ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ascendis Pharma A/S Sponsored ADR stock has an average upside potential 2026 of
32.01%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 393.35 | 653.75 |
| 36.41% | 66.20% | |
| EBITDA Margin | -71.79% | -30.69% |
| 56.15% | 57.25% | |
| Net Margin | -107.40% | -39.32% |
| 44.05% | 63.39% |
16 Analysts have issued a sales forecast Ascendis Pharma A/S Sponsored ADR 2025 . The average Ascendis Pharma A/S Sponsored ADR sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Ascendis Pharma A/S Sponsored ADR EBITDA forecast 2025. The average Ascendis Pharma A/S Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Ascendis Pharma A/S Sponsored ADR Analysts have issued a net profit forecast 2025. The average Ascendis Pharma A/S Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -7.06 | -4.30 |
| 23.68% | 39.09% | |
| P/E | negative | |
| EV/Sales | 15.58 |
8 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast for earnings per share. The average Ascendis Pharma A/S Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Ascendis Pharma A/S Sponsored ADR...
Current Ascendis Pharma A/S Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 25 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 11 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
